NAC as adjuvant therapy for ASD, new double blind study

Discuss autism theories, media stories, and efforts to put ASD on the government agenda here.

Moderator: ModeratorBill

Forum rules
Please limit quotes from articles to five paragraphs. Also, researchers may post study information here.
kulkulkan
Posts: 2075
Joined: Tue Mar 13, 2012 1:37 pm

NAC as adjuvant therapy for ASD, new double blind study

Postby kulkulkan » Wed Jan 14, 2015 4:54 pm

A new randomized double blind study on NAC (as an adjuvant therapy with risperidone though). Saw some statistically significant efficacy in reducing irritability (same as first double blind study) and also some efficacy with respect to hyperactivity/non-compliance.

http://www.ncbi.nlm.nih.gov/pubmed/25580916

Clin Neuropharmacol. 2015 Jan 9. [Epub ahead of print]
N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety.
Nikoo M1, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S.
Author information
Abstract
OBJECTIVES:
According to the proposed interference of N-acetylcysteine (NAC) with pathophysiologic processes of autistic disorders (ADs), we aimed to assess the effectiveness and safety of NAC as an adjunct to risperidone in the treatment of ADs in a randomized, double-blind, clinical trial.

METHODS:
The participants were referred outpatients between 4 and 12 years of age with the diagnosis of ADs and a score of more than 12 on Aberrant Behavior Checklist-Community (ABC-C) Irritability subscale score. The participants were randomized into 2 groups. One group received risperidone plus NAC, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of NAC was 600 to 900 mg/d. The main outcome was mean decrease in the ABC-C irritability subscale score from baseline at 5 and 10 weeks. Changes in other subscales were considered as secondary outcome measures.

RESULTS:
Forty patients completed the 10-week trial. Baseline characteristics including age, sex and body weight, as well as baseline scores in 5 subscales did not demonstrate statistically significant difference between the 2 groups. Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales. By week 10, the NAC group showed significantly more reduction in irritability (P = 0.02) and hyperactivity/noncompliance (P = 0.01) subscales scores.

CONCLUSIONS:
N-acetylcysteine can be considered as an adjuvant therapy for ADs with beneficial therapeutic outcomes.

Return to “Autism Articles, Studies & Politics”